EADO/WCM 2025 | Neoadjuvant therapy: a game-changer in melanoma
Georgina Long
• 3 Apr 2025
Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, reflects on the value of neoadjuvant therapy in melanoma, highlighting its potential to revolutionize the field. Prof. Long highlights that immunotherapy is a game-changer in neoadjuvant therapy, with a high correlation between pathological response and long-term outcome, and that the neoadjuvant approach is superior to adjuvant therapy in terms of event-free survival.This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
